Trial · Interventional

CompletedNot applicableRegistry data

Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

NCTNCT01687582Other idUCL-DIAB-02

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Completed
Phase: Not applicable
Enrollment: 10 participants (actual)
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Other
Design: Allocation not applicable · Open label (no masking)
Countries: 1 country
Belgium
Start: Jan 2012
Primary completion: Dec 2012
Completion: Mar 2013
First posted: 19 Sept 2012 (estimated)
Last update posted: 12 Mar 2019
Conditions: Type 2 Diabetes · Psoriasis

Timeline

1 trial · 1 completed

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

201220132014

N/A
Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients
NCT01687582
Jan 2012 to Mar 2013

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.

Interventions

GLP-1 analogDrug

Arms1

Experimental
GLP-1 analog
Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.

Primary outcomes1

Outcomes the sponsor listed as primary.

Improvement of PASI score
Time frame · 4 to 6 months

Secondary outcomes(6)

Evolution of BMI (body mass index)
Time frame · 4 to 6 months
Registry description
number of patients with weight loss
Evolution of immunological data
Time frame · 4 to 6 months
Registry description
cytokines and T cells
Evolution of histopathological data
Time frame · 4 to 6 months
Registry description
thickness, dermis infiltrate in skin plaques and in control areas
Evolution of glycaemic control
Time frame · 4 to 6 months
Registry description
HbA1c
Evolution of routine laboratory measures
Time frame · 4 to 6 months
Registry description
number of participants with biological adverse effects (pancreatitis enzymes)
Evolution of BMI
Time frame · 4 to 6 months
Registry description
weight

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Case report · 2012

7 results

Improvement of psoriasis during exenatide treatment in a patient with diabetes.

Buysschaert et al. 2012Diabetes & metabolismcited by 38

PMID 22227407DOI 10.1016/j.diabet.2011.11.004PUB-22227407

Full text at the publisher7 results

Publisher page See results (7)

More studies

1 study on this page

PubMed tag: none · 2011

Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.

Hogan et al. 2011Diabetologiacited by 149

PMID 21744074PMC3188710DOI 10.1007/s00125-011-2232-3PUB-21744074

Free to read · publisher termsCC BY-NC

Read at source

Eligibility

Who could join, as posted.

Sex: All
Age: from 20 Years up to 75 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Type 2 diabetic patients treated with oral anti-hyperglycaemic agents and/or insulin and presenting stable psoriasis plaques for at least one year, which failed to respond to previous systemic and/or topical treatments. Exclusion Criteria: * Type 1 diabetes * Secondary diabetes * Liver, renal or pancreatic disease * Previous treatment with GLP-1 agonist or DPP-4 inhibitors agents

PepBank is a research reference. Talk to a doctor before you use any peptide.